Zurcher Kantonalbank Zurich Cantonalbank Has $49.22 Million Holdings in Amgen, Inc. (NASDAQ:AMGN)

Zurcher Kantonalbank Zurich Cantonalbank lessened its position in shares of Amgen, Inc. (NASDAQ:AMGN) by 3.0% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 259,066 shares of the medical research company’s stock after selling 7,900 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Amgen were worth $49,217,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Oregon Public Employees Retirement Fund increased its stake in Amgen by 20,103.6% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 31,424,215 shares of the medical research company’s stock worth $161,000 after buying an additional 31,268,677 shares in the last quarter. Norges Bank purchased a new stake in shares of Amgen in the fourth quarter valued at approximately $1,283,248,000. BlackRock Inc. grew its position in shares of Amgen by 2.0% in the fourth quarter. BlackRock Inc. now owns 46,127,396 shares of the medical research company’s stock valued at $8,979,621,000 after purchasing an additional 906,568 shares in the last quarter. Ellis Investment Partners LLC grew its position in shares of Amgen by 18,906.7% in the first quarter. Ellis Investment Partners LLC now owns 605,934 shares of the medical research company’s stock valued at $605,000 after purchasing an additional 602,746 shares in the last quarter. Finally, Geode Capital Management LLC grew its position in shares of Amgen by 5.8% in the fourth quarter. Geode Capital Management LLC now owns 8,850,224 shares of the medical research company’s stock valued at $1,720,250,000 after purchasing an additional 482,760 shares in the last quarter. 77.24% of the stock is owned by institutional investors and hedge funds.

AMGN stock traded up $2.07 during midday trading on Monday, hitting $186.35. The stock had a trading volume of 1,670,794 shares, compared to its average volume of 2,980,875. The company has a market cap of $112.40 billion, a price-to-earnings ratio of 12.94, a PEG ratio of 2.24 and a beta of 1.16. The company has a current ratio of 2.77, a quick ratio of 2.53 and a debt-to-equity ratio of 2.71. Amgen, Inc. has a 12-month low of $166.30 and a 12-month high of $210.19. The business has a 50-day moving average price of $175.68.

Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, April 30th. The medical research company reported $3.56 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $3.45 by $0.11. Amgen had a net margin of 34.00% and a return on equity of 71.02%. The firm had revenue of $5.56 billion during the quarter, compared to analysts’ expectations of $5.55 billion. During the same period in the previous year, the company earned $3.47 EPS. Amgen’s revenue for the quarter was up .1% on a year-over-year basis. On average, equities research analysts anticipate that Amgen, Inc. will post 13.91 EPS for the current fiscal year.

In related news, Director Ronald D. Sugar sold 2,000 shares of the company’s stock in a transaction on Wednesday, May 1st. The shares were sold at an average price of $175.73, for a total transaction of $351,460.00. Following the completion of the sale, the director now directly owns 15,092 shares of the company’s stock, valued at approximately $2,652,117.16. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Over the last ninety days, insiders have sold 6,000 shares of company stock valued at $1,089,180. 0.25% of the stock is owned by corporate insiders.

Several research analysts recently weighed in on AMGN shares. BMO Capital Markets started coverage on Amgen in a research report on Thursday, March 14th. They issued an “outperform” rating and a $228.00 price objective for the company. Mizuho set a $208.00 price objective on Amgen and gave the stock a “buy” rating in a research report on Friday, March 22nd. Cantor Fitzgerald restated a “hold” rating and set a $221.00 price target on shares of Amgen in a research note on Monday, April 1st. Zacks Investment Research upgraded Amgen from a “hold” rating to a “buy” rating and set a $215.00 price target on the stock in a research note on Tuesday, April 2nd. Finally, BidaskClub cut Amgen from a “hold” rating to a “sell” rating in a research note on Tuesday, April 23rd. Ten research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. Amgen currently has an average rating of “Buy” and a consensus target price of $208.35.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.

Featured Story: What is a stock buyback?

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.